A citation-based method for searching scientific literature

Laura J Esserman, Donald A Berry, Angela DeMichele, Lisa Carey, Sarah E Davis, Meredith Buxton, Cliff Hudis, Joe W Gray, Charles Perou, Christina Yau, Chad Livasy, Helen Krontiras, Leslie Montgomery, Debasish Tripathy, Constance Lehman, Minetta C Liu, Olufunmilayo I Olopade, Hope S Rugo, John T Carpenter, Lynn Dressler, David Chhieng, Baljit Singh, Carolyn Mies, Joseph Rabban, Yunn-Yi Chen, Dilip Giri, Laura van 't Veer, Nola Hylton. J Clin Oncol 2012
Times Cited: 289







List of co-cited articles
615 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
53

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
40

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
24

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
23

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, Rebekah Gould, Xian Yu, Ya Zhang, Mei Liu, Andrew Walls, Alex Bousamra, Maheshwari Ramineni, Bruno Sinn,[...]. J Clin Oncol 2017
280
21

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
836
18

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
660
17


Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
619
15

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
14

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
Hope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, Christina Yau, Laura J van 't Veer, Meredith B Buxton, Michael Hogarth, Nola M Hylton, Melissa Paoloni, Jane Perlmutter,[...]. N Engl J Med 2016
324
13

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
12


Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
Nola M Hylton, Jeffrey D Blume, Wanda K Bernreuter, Etta D Pisano, Mark A Rosen, Elizabeth A Morris, Paul T Weatherall, Constance D Lehman, Gillian M Newstead, Sandra Polin,[...]. Radiology 2012
269
12

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
11

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Nehmat Houssami, Petra Macaskill, Gunter von Minckwitz, Michael L Marinovich, Eleftherios Mamounas. Eur J Cancer 2012
288
11

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.
B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, R G Margolese, A B Cruz, E R Fisher, D L Wickerham, N Wolmark,[...]. J Clin Oncol 1997
11

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, T L Smith, F C Ames, K K Hunt, K Dhingra, R L Theriault, G Singh, S M Binkley, N Sneige,[...]. J Clin Oncol 1999
11

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
551
11

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
524
10

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
10

Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, Maggie C U Cheang, Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu,[...]. J Clin Oncol 2009
9

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005
752
9

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Laura J Esserman, Donald A Berry, Maggie C U Cheang, Christina Yau, Charles M Perou, Lisa Carey, Angela DeMichele, Joe W Gray, Kathleen Conway-Dorsey, Marc E Lenburg,[...]. Breast Cancer Res Treat 2012
229
9


Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
781
9

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
Chafika Mazouni, Florentia Peintinger, Shu Wan-Kau, Fabrice Andre, Ana M Gonzalez-Angulo, W Fraser Symmans, Funda Meric-Bernstam, Vicente Valero, Gabriel N Hortobagyi, Lajos Pusztai. J Clin Oncol 2007
187
9

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys. Breast 2003
505
9

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, Sibylle Loibl, Eleftherios P Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo,[...]. N Engl J Med 2019
784
9


Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Alfredo Berruti, Vito Amoroso, Fabio Gallo, Valentina Bertaglia, Edda Simoncini, Rebecca Pedersini, Laura Ferrari, Alberto Bottini, Paolo Bruzzi, Maria Pia Sormani. J Clin Oncol 2014
145
8

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
8

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
8

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, W Fraser Symmans, Nuhad Ibrahim, Massimo Cristofanilli, Keith Anderson, Kenneth R Hess, James Stec, Mark Ayers, Peter Wagner,[...]. Clin Cancer Res 2005
8

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
8

Adaptive Randomization of Neratinib in Early Breast Cancer.
John W Park, Minetta C Liu, Douglas Yee, Christina Yau, Laura J van 't Veer, W Fraser Symmans, Melissa Paoloni, Jane Perlmutter, Nola M Hylton, Michael Hogarth,[...]. N Engl J Med 2016
210
8

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
Nola M Hylton, Constantine A Gatsonis, Mark A Rosen, Constance D Lehman, David C Newitt, Savannah C Partridge, Wanda K Bernreuter, Etta D Pisano, Elizabeth A Morris, Paul T Weatherall,[...]. Radiology 2016
112
8


5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Starosławska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini,[...]. Lancet Oncol 2016
369
8

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren,[...]. Lancet 2012
882
8

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Michael Untch, Peter A Fasching, Gottfried E Konecny, Stephan Hasmüller, Annette Lebeau, Rolf Kreienberg, Oumar Camara, Volkmar Müller, Andreas du Bois, Thorsten Kühn,[...]. J Clin Oncol 2011
349
8

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Kristine R Broglio, Melanie Quintana, Margaret Foster, Melissa Olinger, Anna McGlothlin, Scott M Berry, Jean-François Boileau, Christine Brezden-Masley, Stephen Chia, Susan Dent,[...]. JAMA Oncol 2016
140
8

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
305
8

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, Aurelia Noske, Marc Roller, Berit Maria Müller, Martina Komor, Jan Budczies, Silvia Darb-Esfahani, Ralf Kronenwett, Claus Hanusch,[...]. J Clin Oncol 2010
7

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Christos Hatzis, Lajos Pusztai, Vicente Valero, Daniel J Booser, Laura Esserman, Ana Lluch, Tatiana Vidaurre, Frankie Holmes, Eduardo Souchon, Hongkun Wang,[...]. JAMA 2011
396
7

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
533
7

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D Lehmann, Jennifer A Pietenpol, Gabriel N Hortobagyi,[...]. Clin Cancer Res 2013
427
7

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
A D Barker, C C Sigman, G J Kelloff, N M Hylton, D A Berry, L J Esserman. Clin Pharmacol Ther 2009
425
7

The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Oluwadamilola M Fayanju, Yi Ren, Samantha M Thomas, Rachel A Greenup, Jennifer K Plichta, Laura H Rosenberger, Nina Tamirisa, Jeremy Force, Judy C Boughey, Terry Hyslop,[...]. Ann Surg 2018
71
9

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
619
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.